Milk Thistle for Health & Longevity - Quick Reference Sheet

Milk Thistle for Health & Longevity

Created on 07/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Milk thistle's active extract, silymarin, helps shield liver cells as an antioxidant. Its most reliable effect is modestly lowering raised liver enzymes, with better blood sugar in type 2 diabetes and smaller shifts in blood fats. Benefits show mainly in those starting with elevated markers. Safe and low-cost, but effects are unproven and product quality varies. (Full Review)

Protocol

Standard Dose
~140 mg 2–3× daily
~280–420 mg/day silymarin; trials used ~200–600 mg/day
Formulation
70–80% silymarin extract
Silybin-phosphatidylcholine (phytosome) forms absorb far better
Timing
Split doses, with meals
2–3 divided doses with fat-containing food; short ~6 h half-life
Time to effect
Liver Enzymes
Weeks–months
Most trials run 8–24 weeks; judge by labs, not sensation
Blood Sugar
Weeks–months
Metabolic markers reassessed at ~8–12 weeks
Lipids & Inflammation
Weeks–months
Smaller, slower shifts; seen mainly in metabolic populations

Benefits

Contraindications
  • Known Asteraceae-family allergy (ragweed, daisies, marigolds, chrysanthemums)
  • Decompensated liver disease (Child-Pugh Class C)
  • Pregnancy and breastfeeding
  • Hormone-sensitive conditions
Key Interactions
  • CYP2C9/CYP3A4 narrow-index drugs (warfarin, phenytoin, simvastatin, sirolimus)
  • Antidiabetic medications (insulin, sulfonylureas)
  • Glucuronidated drugs (raloxifene)
  • Additive blood-sugar-lowering supplements (berberine, chromium, cinnamon)

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal discomfort; product quality variability and under-dosing
  • Low: Allergic and hypersensitivity reactions; additive blood-glucose lowering
  • Speculative: Theoretical estrogenic effects in hormone-sensitive conditions; pharmacokinetic drug interactions

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) ~10–25 U/L Primary marker of liver-cell stress; most likely to respond
Aspartate aminotransferase (AST) ~10–25 U/L Complements ALT; together track liver-cell injury
Gamma-glutamyl transferase (GGT) ~10–30 U/L Oxidative stress, bile flow, and alcohol effect on the liver
Hemoglobin A1c (HbA1c) <5.4% Tracks whether the metabolic/glycemic benefit is materializing
Fasting glucose 75–90 mg/dL Shorter-term readout of glucose control
Lipid panel (LDL, triglycerides) Triglycerides <90 mg/dL; LDL context-dependent Detects the modest lipid effect seen in metabolic populations
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L Captures the anti-inflammatory signal, if any

Cadence: Baseline before starting; retest at ~8–12 weeks on a stable dose, then every 6–12 months if continued

Qualitative Assessment

  • Energy levels — daytime energy and reduced sluggishness
  • Digestive comfort — supplement tolerance and absence of gastrointestinal upset
  • Alcohol- or medication-related symptoms — perceived change in handling alcohol or hepatotoxic-drug exposure